TNF and ataxia telangiectasia: In the maintenance study AT-IR subgroup, 93.4% of patients had prior exposure to anti-TNF therapy, 52.8% had prior exposure to vedolizumab, and 20.0% had prior exposure to JAK inhibitors (Table 2).